EVMN — Evommune Cashflow Statement
0.000.00%
Last trade - 00:00- $713.44m
- $564.77m
- $13.00m
Annual cashflow statement for Evommune, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Net Income/Starting Line | -34.1 | -66.8 | -68.9 |
| Depreciation | |||
| Non-Cash Items | -0.261 | -0.098 | -4.84 |
| Unusual Items | |||
| Other Non-Cash Items | |||
| Changes in Working Capital | 3.34 | 7.42 | -4.12 |
| Change in Prepaid Expenses | |||
| Change in Accounts Payable | |||
| Change in Accrued Expenses | |||
| Change in Other Liabilities | |||
| Cash from Operating Activities | -30 | -58.2 | -76.4 |
| Capital Expenditures | -0.118 | -0.088 | -0.235 |
| Purchase of Fixed Assets | |||
| Other Investing Cash Flow Items | -48.3 | -3.9 | -115 |
| Sale/Maturity of Investment | |||
| Purchase of Investments | |||
| Cash from Investing Activities | -48.4 | -3.99 | -115 |
| Financing Cash Flow Items | — | — | -1.22 |
| Other Financing Cash Flow | |||
| Net Issuance / Retirement of Stock | |||
| Net Issuance / Retirement of Debt | |||
| Cash from Financing Activities | 63.8 | 49.4 | 221 |
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | -14.7 | -12.8 | 29 |